Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 1Phase 2 Interventional Results available

A Study of Weekly Carfilzomib in Combination With Dexamethasone for Progressive Multiple Myeloma

ClinicalTrials.gov ID: NCT01677858

Public ClinicalTrials.gov record NCT01677858. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 10, 2026, 8:35 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1/2 Study of Weekly Carfilzomib in Combination With Dexamethasone for Progressive Multiple Myeloma

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The study had the following primary objectives: * Phase 1: to determine the maximum tolerated dose (MTD) of once-weekly (QW) carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior therapies * Phase 2: to estimate the overall response rate (ORR) for patients with relapsed or refractory multiple myeloma who received 1 to 3 prior therapies treated with carfilzomib and dexamethasone QW at the MTD established in phase 1.

Study identification

NCT ID
NCT01677858
Recruitment status
Completed
Study type
Interventional
Phase
Phase 1, Phase 2
Lead sponsor
Amgen
Industry
Enrollment
116 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 3, 2012
Primary completion
Jul 21, 2016
Completion
Oct 30, 2018
Last update posted
Sep 22, 2022

2012 – 2018

United States locations

U.S. sites
35
U.S. states
15
U.S. cities
33
Facility City State ZIP Site status
Arizona Oncology Associates Tucson Arizona
Comprehensive Blood and Cancer Center (CCBC) Bakersfield California
California Cancer Associates for Research and Excellence Encinitas California
Robert A. Moss, M.D., FACP, Inc. Fountain Valley California
California Cancer Associates for Research and Excellence Fresno California
Cedars-Sinai Medical Center Los Angeles California
Monterey Bay Oncology Salinas California
Sansum Clinic Santa Barbara California
Central Coast Medical Oncology Corporation Santa Maria California
James R. Berenson M.D. Inc. West Hollywood California
The Oncology Insititute of Hope and Innovation Whittier California
Rocky Mountain Cancer Centers Denver Colorado
Florida Cancer Specialists - South Fort Myers Florida
Florida Cancer Specialists - North Tampa Florida
Illinois Cancer Care Galesburg Illinois
Illinois Cancer Specialists Hinsdale Illinois
Illinois Cancer Specialists Niles Illinois
Fort Wayne Oncology & Hematology Fort Wayne Indiana
Horizon Oncology Research, Inc. Lafayette Indiana
Center for Cancer and Blood Disorders (CCBD) Bethesda Maryland
Hematology-Oncology Associates of Northern NJ, PA Morristown New Jersey
New Mexico Cancer Care Alliance Albuquerque New Mexico
Clinical Research Alliance New York New York
Hudson Valley Hematology Oncology Associates Poughkeepsie New York
Willamette Valley Cancer Institute and Research Center Eugene Oregon
Tennessee Oncology, PLLC Chattanooga Tennessee
St. Joseph Regional Cancer Center Bryan Texas
Millennium Oncology Houston Texas
Waldron Medical Research and Development Center Houston Texas
Cancer Care Centers of South Texas San Antonio Texas
Center at Cancer Therapy & Research Center at The University of Texas Health Science Center at San Antonio San Antonio Texas
Blood and Cancer Center of East Texas Tyler Texas
Shenandoah Oncology, PC Winchester Virginia
Northwest Cancer Specialists Vancouver Washington
Yakima Valley Memorial Hospital/ North Star Lodge Yakima Washington

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01677858, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 22, 2022 · Synced Sep 10, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01677858 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →